I am interested in novel strategies that reduce the severity and progression of dry Age-related Macular Degeneration (AMD). I aim to understand the factors that cause photoreceptors to die, and identify novel ways to protect them from degeneration. My recent work focuses on the role of microRNA (miRNA) in the degenerating retina, and examines their potential use as therapeutics. This ground-breaking work has been funded by competitive funding agencies (Ophthalmic Research Institute of Australia, Retina Australia and NHMRC) as well as industry (Thermo Fisher Scientific, Beta Therapeutics, EyeCo, MuPharma and Bayer) and through innovation investment funding (Discovery Translational Fund). I have also developed a non-invasive treatment strategy to revolutionise the management of premature infants at risk of developing Retinopathy of Prematurity (ROP) and increasing survivability, currently and ongoing collaboration with members of the ANU Medical School and Canberra Hospital.
Research led by Associate Professor Riccardo Natoli and his team explores the causes behind the deterioration of the retina, the part of the eye responsible for converting light to an electrical signal that our brain can understand, with age. There focus is on studying the currently incurable age-related macular degeneration (AMD). This disease leads to irreparable loss of retina specific cells causing permanent blindness. We have a 'Clear Vision' of what is required to reduce the progression of AMD and other retinal diseases, and have developed a number of potential therapeutics which could prevent retinal degeneration by targeting inflammation and oxidative stress, two major facets of retinal degenerations.
Visit: www.clearvision.com for more information on his research and his team